Serum fibrosis scores as predictors of liver fibrosis and long-term outcomes in metabolic dysfunction-associated steatotic liver disease, including cirrhosis
Retrospective analysis identifies FIB-4 as the strongest predictor of fibrosis and cirrhosis outcomes in MASLD patients, highlighting its diagnostic value.
Key Points
FIB-4 was the most accurate predictor of advanced fibrosis in METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE patients.
Multivariate analysis identified fibrosis stage (HR: 3.045) as a key predictor for de novo CIRRHOSIS in the cohort.
The study evaluated the diagnostic performance of fibrosis scores using ROC analysis, with FIB-4 achieving an AUC of 0.77.
Long-term outcomes were assessed based on factors like age, albumin, and HbA1c, with significant associations to survival noted.